PLYX
Polaryx Therapeutics·NASDAQ
--
--(--)
--
--(--)
PLYX fundamentals
During Q4 2025, Polaryx Therapeutics (PLYX) reported revenue of --, a YoY change of 0.00%. Net income was -1.50M, a YoY change of -106.78%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2024 | Q4,2024 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jul 1, 2024 | Oct 1, 2024 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Sep 30, 2024 | Dec 31, 2024 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Pretax Income From Continuing Operations | -771.00K -- | -723.00K -- | -1.43M -85.47% | -1.50M -106.78% | -- -- |
Net Income | -771.00K -- | -723.00K -- | -1.43M -85.47% | -1.50M -106.78% | -- -- |
Total Comprehensive Income | -771.00K -- | -723.00K -- | -1.43M -85.47% | -1.50M -106.78% | -- -- |
Basic EPS | -0.02 -- | -- -- | -0.03 -50.00% | -- -- | -- -- |
Diluted EPS | -0.02 -- | -- -- | -0.03 -50.00% | -- -- | -- -- |
You can ask Aime
What factors drove the changes in Polaryx Therapeutics's revenue and profit?What is Polaryx Therapeutics's gross profit margin?What were the key takeaways from Polaryx Therapeutics’s earnings call?What does Polaryx Therapeutics do and what are its main business segments?Did Polaryx Therapeutics beat or miss consensus estimates last quarter?What is the market's earnings forecast for Polaryx Therapeutics next quarter?What is the revenue and EPS growth rate for Polaryx Therapeutics year over year?What is Polaryx Therapeutics's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
